BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21447744)

  • 1. Differentiation of NUT midline carcinoma by epigenomic reprogramming.
    Schwartz BE; Hofer MD; Lemieux ME; Bauer DE; Cameron MJ; West NH; Agoston ES; Reynoird N; Khochbin S; Ince TA; Christie A; Janeway KA; Vargas SO; Perez-Atayde AR; Aster JC; Sallan SE; Kung AL; Bradner JE; French CA
    Cancer Res; 2011 Apr; 71(7):2686-96. PubMed ID: 21447744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
    Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
    Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
    French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
    Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of diagnosing NUT midline carcinoma.
    French CA
    Head Neck Pathol; 2013 Mar; 7(1):11-6. PubMed ID: 23463074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of NUT midline carcinoma.
    French CA
    Annu Rev Pathol; 2012; 7():247-65. PubMed ID: 22017582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns.
    Zee BM; Dibona AB; Alekseyenko AA; French CA; Kuroda MI
    PLoS One; 2016; 11(10):e0163820. PubMed ID: 27698495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
    French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
    Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
    Yan J; Diaz J; Jiao J; Wang R; You J
    J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytologic findings of NUT midline carcinoma in the hilum of the lung.
    Policarpio-Nicolas ML; de Leon EM; Jagirdar J
    Diagn Cytopathol; 2015 Sep; 43(9):739-42. PubMed ID: 26138851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
    Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
    Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
    Fang W; French CA; Cameron MJ; Han YD; Liu HG
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates.
    Sun H; McGuire MF; Zhang S; Brown RE
    Ann Clin Lab Sci; 2015; 45(6):692-701. PubMed ID: 26663801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
    Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
    Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
    Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
    Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.